Holen Sie sich die Stockscreener-App
754.35
3.00%
21.94
Handel nachbörslich:
752.00
-2.35
-0.31%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LLY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$732.41
Offen:
$750.45
24-Stunden-Volumen:
3.46M
Relative Volume:
0.97
Marktkapitalisierung:
$677.53B
Einnahmen:
$45.04B
Nettoeinkommen (Verlust:
$10.59B
KGV:
64.42
EPS:
11.71
Netto-Cashflow:
$414.30M
1W Leistung:
+4.23%
1M Leistung:
-7.27%
6M Leistung:
-18.84%
1J Leistung:
+0.36%
1-Tages-Spanne:
$734.52
$759.56
1-Wochen-Bereich:
$689.00
$763.50
52-Wochen-Spanne:
$677.09
$972.53
Lilly Eli Co Stock (LLY) Company Profile
Firmenname
Lilly Eli Co
Sektor
Telefon
(317) 276-2000
Adresse
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Vergleichen Sie LLY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
754.35 | 677.53B | 45.04B | 10.59B | 414.30M | 11.71 |
|
JNJ
Johnson Johnson
|
154.36 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
ABBV
Abbvie Inc
|
179.10 | 316.82B | 56.33B | 4.28B | 17.83B | 2.40 |
|
NVO
Novo Nordisk Adr
|
66.06 | 293.24B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
109.46 | 216.19B | 51.72B | 11.94B | 13.81B | 5.88 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-09-13 | Fortgesetzt | Citigroup | Buy |
| 2024-08-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Herabstufung | DZ Bank | Buy → Hold |
| 2024-02-16 | Bestätigt | Morgan Stanley | Overweight |
| 2023-12-21 | Herabstufung | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-20 | Fortgesetzt | UBS | Buy |
| 2023-08-09 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-26 | Bestätigt | Citigroup | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-24 | Bestätigt | BofA Securities | Buy |
| 2023-05-24 | Bestätigt | UBS | Buy |
| 2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-15 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-09-22 | Hochstufung | UBS | Neutral → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-03-10 | Eingeleitet | Daiwa Securities | Outperform |
| 2022-01-21 | Hochstufung | DZ Bank | Hold → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-16 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-16 | Bestätigt | BofA Securities | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-10-11 | Hochstufung | Berenberg | Hold → Buy |
| 2021-09-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-05 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-06-24 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-12-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-09-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-21 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2019-12-18 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-04-24 | Hochstufung | Edward Jones | Hold → Buy |
| 2019-04-11 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2019-01-23 | Eingeleitet | UBS | Buy |
| 2018-11-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-10-31 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-10-01 | Bestätigt | SunTrust | Buy |
| 2018-09-26 | Fortgesetzt | JP Morgan | Overweight |
Alle ansehen
Lilly Eli Co Aktie (LLY) Neueste Nachrichten
Eli Lilly's Mounjaro launch in India ignites wave of weight-loss enquiries - Yahoo
Verve’s shares jump by more than 26% on Lilly-partnered gene therapy data - Pharmaceutical Technology
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today - The Motley Fool
Jim Cramer on Eli Lilly and Company (LLY): “The Fastest Factory I’ve Ever Seen” - Insider Monkey
Eli Lilly Stock: A Deep Dive Into Analyst Perspectives (7 Ratings) - Benzinga
Eli Lilly (LLY) Challenges OrderlyMeds Over Compounded Tirzepati - GuruFocus
Eli Lilly (LLY) Sees Price Target Reduced by Guggenheim Ahead of Earnings | LLY Stock News - GuruFocus
Eli Lilly price target lowered to $928 from $973 at Guggenheim - TipRanks
Eli Lilly (LLY) Shows Strong Revenue Growth and Strategic Expans - GuruFocus
Eli Lilly (LLY) Boosts U.S. Manufacturing with $50 Billion Inves - GuruFocus
Eli Lilly (LLY) Boosts U.S. Manufacturing with $50 Billion Investment - GuruFocus
Eli Lilly Stock: Some Big News Is Incoming (NYSE:LLY) - Seeking Alpha
Eli Lilly's Obesity Drug Maintains Weight Loss for Three Years - MarketScreener
Notable analyst calls this week: Apple, Eli Lilly and Verizon stocks among top picks - Seeking Alpha
Novo, Lilly Patent Moves Keep GLP-1 Prices High, Report Says (3) - Bloomberg Law News
Lilly’s Zepbound Keeps Weight Off for Three Years, Study Finds - Bloomberg
Why Eli Lilly and Company (LLY) Is the Best Medical Stock to Buy According to Billionaires - Insider Monkey
Eli Lilly Drops $1.57B Bombshell--And Wall Street Shrugs It Off - Yahoo Finance
Eli Lilly Reverses Its Recent Run On Market Malaise. Is It A Sell? - Investor's Business Daily
Compounding pharmacy says Eli Lilly’s cease and desist letter means “nothing” - Sherwood News
OrderlyMeds Defies Eli Lilly (LLY) Cease-and-Desist Over Compoun - GuruFocus
Novartis Commits $23 Billion To Expand US Manufacturing Over Five Years, Despite Tariffs Uncertainties - Benzinga
Eli Lilly (LLY) Anticipates Q1 2025 Earnings Impact from Researc - GuruFocus
Personalized Medicine Market Forecast Report and Company Analysis 2025-2033 Featuring Abbott, GE, Aadi Bioscience, Illumina, QIAGEN, Eli Lilly and Co, Takeda, AbbVie, F. Hoffmann-La RocheResearchAndMarkets.com | FinancialContent - FinancialContent
Novo Nordisk and Eli Lilly Bring Weight Loss Contest to India - outlookbusiness.com
The Zacks Analyst Blog Highlights Eli Lilly, American Express, Thermo Fisher, Steel Partners and Oil-Dri - Yahoo Finance
ITC Blocks Imports Of Copycats Of Eli Lilly Weight Loss Drug - Law360
Top Research Reports for Eli Lilly, American Express & Thermo Fisher - Yahoo Finance
Eli Lilly Estimates Q1 2025 Acquired IPR&D Charges Approximately $1.72 To EPS - MarketScreener
Behind the Scenes of Eli Lilly's Latest Options Trends - Benzinga
GLP-1 Agonists Market Key Players Analysis- Eli Lilly and Company, Sanofi, AstraZeneca, Novo Nordisk. - openPR.com
Q4 Earnings Highs And Lows: Eli Lilly (NYSE:LLY) Vs The Rest Of The Branded Pharmaceuticals Stocks - Yahoo Finance
Lilly backs $41M investment in Longwood Fund spinout - The Business Journals
FDA: Pharmacies' Bid To Keep Making Eli Lilly Drug Is 'Absurd' - Law360
Eli Lilly and Company (LLY): One of the High Growth Dividend Paying Stocks to Invest in - Insider Monkey
Trump-Powered Medicare Setback Adds Bullish Impetus for Eli Lilly & Co (LLY) Stock - markets.businessinsider.com
Lobbying Update: $60,000 of ELI LILLY AND COMPANY lobbying was just disclosed - Nasdaq
Eli Lilly & Co (LLY) Gets a Buy from Bank of America Securities - The Globe and Mail
Top Stock Movers Now: Delta, Apple, Eli Lilly, and More - Investopedia
Why Roche Holding, Eli Lilly, and AstraZeneca Stocks Dropped Today - The Motley Fool
Eli Lilly & Company (LLY): Among Defensive Stocks Billionaire Ken Fisher Is Betting On - Insider Monkey
Eli Lilly CEO David Ricks Just Delivered Terrible News to Investors: Should You Sell the Stock? - The Motley Fool
Morgan Stanley Adjusts Price Target on Eli Lilly and Co. to $1,124 From $1,146, Keeps Overweight Rating - MarketScreener
Concerns Raised Over DTC Platform for Alzheimer’s Diagnosis - Medscape
Eli Lilly and Novo Nordisk: Obesity Drug Coverage in Medicare Not a Straight Path - Morningstar
Jim Cramer on Eli Lilly and Company (LLY): “You Don’t Sell Lilly” — “David Ricks Is a Visionary” - Insider Monkey
Eli Lilly (LLY) Upgraded by Goldman Sachs Amid Biopharma Reviews - GuruFocus
LLY vs. NVO: Which Weight-Loss Drug Stock is a Stronger Play Now? - TradingView
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Eli Lilly (LLY) Upgraded by Goldman Sachs Amid Market Volatility - GuruFocus
Goldman Sachs raises Eli Lilly stock rating to buy, lowers target - Investing.com
Finanzdaten der Lilly Eli Co-Aktie (LLY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.73%
0.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):